BRIEF published on 06/19/2025 at 17:51, 1 year 4 months ago Présentations scientifiques clés sur l'Imeglimine à l'ADA 2025 Diabète Présentations Scientifiques Sumitomo Pharma Potentiel Thérapeutique Iméglimine
PRESS RELEASE published on 06/19/2025 at 17:46, 1 year 4 months ago Inside Information / Other news releases Poxel presents new Imeglimin data at ADA 2025 diabetes conference, highlighting therapeutic potential. Key presentations by Japanese experts Diabetes Therapeutic Potential Poxel Imeglimin ADA 2025
PRESS RELEASE published on 06/19/2025 at 17:46, 1 year 4 months ago Informations privilégiées / Autres communiqués Des leaders d'opinion présentent le potentiel thérapeutique de l'Imeglimine lors de l'ADA 2025, le plus grand congrès sur le diabète. POXEL SA annonce cinq présentations à Chicago, Illinois Congrès Diabète Poxel SA Iméglimine ADA 2025
BRIEF published on 06/06/2025 at 19:10, 1 year 4 months ago Poxel : Détails sur le capital social et les droits de vote Droits De Vote Capital Social Actions Informations Réglementées Poxel
BRIEF published on 06/06/2025 at 19:10, 1 year 4 months ago Poxel: Details of share capital and voting rights Share Capital Voting Rights Actions Regulated Information Poxel
PRESS RELEASE published on 06/06/2025 at 19:05, 1 year 4 months ago Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital Poxel communique le nombre d'actions et de droits de vote composant son capital social conformément aux réglementations en vigueur Capital Social Informations Réglementées Biopharmaceutique Maladies Métaboliques Poxel
BRIEF published on 05/28/2025 at 07:35, 1 year 5 months ago TWYMEEG® Data Unveiled at Japan Diabetes Society Meeting Clinical Trials Diabetes Treatment TWYMEEG® Poxel SA Japan Diabetes Society
BRIEF published on 05/28/2025 at 07:35, 1 year 5 months ago Les données TWYMEEG® dévoilées lors de la réunion de la Société japonaise du diabète Essais Cliniques Traitement Du Diabète TWYMEEG® Poxel SA Société Japonaise Du Diabète
PRESS RELEASE published on 05/28/2025 at 07:30, 1 year 5 months ago Inside Information / Other news releases New clinical and scientific data on TWYMEEG® to be presented at the 68th Annual Meeting of the Japan Diabetes Society, showcasing efficacy, safety, and benefits in diverse patient groups Clinical Data Scientific Data TWYMEEG® Sumitomo Pharma Japan Diabetes Society
PRESS RELEASE published on 05/28/2025 at 07:30, 1 year 5 months ago Informations privilégiées / Autres communiqués Présentation à venir de nouvelles données cliniques et scientifiques sur TWYMEEG® lors du 68ème Congrès annuel de la Société Japonaise du Diabète par Poxel SA, société biopharmaceutique au stade clinique Japon Diabète Poxel TWYMEEG Données Cliniques
Published on 10/30/2026 at 23:35, 19 hours 3 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 19 hours 8 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 21 hours 51 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 23 hours 38 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 3 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/31/2026 at 16:35, 2 hours 2 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 19 hours 49 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 19 hours 38 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 19 hours 38 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
